CClinicalTrials.gg
Status unknownNCT03009253TRLAPAUpdated Jan 4, 2017

Translational Research on Locally Advanced Pancreatic Adenocarcinoma

An interventional study of order of treatment in Pancreatic Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-04.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to find the best neoadjuvant therapy for pancreatic adenocarcinoma.

Read the detailed description

The trial is prepared to be registered on the clinicaltrail.gov. Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent,the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences.

Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.

Data dictionary that contains detailed descriptions of each variable used by the registry,including the source of the variable, coding information, and normal ranges if relevant.Standard Operating Procedures to address registry operations and analysis activities,such as participants recruitment, data collection, data management, data analysis,reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.

Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 80 participants to take part in the trail.

The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit at least for two years.

Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results.

Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P \< 0.05.

02

Conditions studied

  • Pancreatic Cancer

Keywords

  • Neoadjuvant therapy
  • Pancreatic Cancer
03

In context

Adenocarcinoma

2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.

This study's planned enrollment of 40 is below the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.

Browse Adenocarcinoma studies →

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 373 studies on the registry; 270 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • have cytologic or pathological proof of pancreatic adenocarcinoma without surgery contraindication score of ECOG is between 0 and 1 evaluation of CT is unresectable

Exclusion criteria

Exclusion Criteria:

  • metastatic pancreatc adenocarcinoma malignant tumors history allergic to 5-FU have difficulty in swallowing joined other clinical trails cardiac and renal disease active infection
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Concurrent chemoradiotherapy(CCRT) Group

    Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)

    Other: order of treatment

  • Experimental
    Chemotherapy Group

    Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles) Followed by Concurrent chemoradiotherapy: (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks)

    Other: order of treatment

Interventions

  • Otherorder of treatment

    the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.

06

What researchers measure

Primary outcomes

  1. translational resection rate

    Time frame: half a year

Secondary outcomes

  1. progression-free survival

    PFS

    Time frame: 2 years

  2. Local control rate

    LCR

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Cancer Institute and Hospital ,China Academy of Medical Sciences
    Beijing, Beijing 10021, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03009253
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Responsible party
Chengfeng Wang (Director of department of pancreatic and gastric surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Jan 4, 2017
Start date
Jul 2015
Primary completion
Dec 2018 (estimated)
Completion
Dec 2019 (estimated)
Last update
Jan 4, 2017

Study contacts

Xu Che, M.D
Contact
xu.che@hotmail.com
8610-87787120
Yunmian Chu, M.D.
Contact
chuyunmian@foxmail.com
+8618101333727
Chengfeng Wang, B.A.
principal investigator · Investigator CancerIHCAMS

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion